Synthetic Aβ peptides acquire prion-like properties in the brain

Xiangzhu Xiao1, Ignazio Cali1,2,3, Jue Yuan1

  • 1Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.

Oncotarget
|December 3, 2014
PubMed

Insights

Alzheimer's disease amyloid-beta (Aβ) peptides gain protease resistance when introduced to human brain tissue, suggesting cofactors influence Aβ's disease-associated properties.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pathology

Background:

  • Alzheimer's disease (AD) pathogenesis involves amyloid-beta (Aβ) plaque formation, potentially initiated by seeded Aβ peptides.
  • Aβ in AD exhibits protease resistance, similar to misfolded prion proteins (PrPSc), but the biochemical basis is unclear.

Purpose of the Study:

  • To investigate the biochemical and morphological characteristics of synthetic and brain-derived Aβ.
  • To understand the factors contributing to Aβ's protease resistance in the context of Alzheimer's disease.

Main Methods:

  • In vitro assays
  • Histoblotting of AD brain tissue
  • Electron microscopy
  • Proteinase K (PK) digestion assays

Main Results:

  • Synthetic Aβ40 and Aβ42 peptides are soluble and fully digested by PK.
  • Aβ species from AD brains are insoluble and PK-resistant.
  • When added to human brain homogenates, synthetic Aβ40 and Aβ42 become insoluble and PK-resistant.
  • Electron microscopy revealed differences in fibril formation between synthetic Aβ40 and Aβ42.

Conclusions:

  • The human brain contains cofactors that confer PrPSc-like properties, including protease resistance, to synthetic Aβ peptides.
  • These cofactors may play a crucial role in the seeding and propagation of Aβ pathology in Alzheimer's disease.